Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma.
|
31723000 |
2020 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downregulation of the miR-221/222 cluster diminished the invasion, migration, proliferation, and angiogenesis with reduced protein levels of matrix metalloproteinase-2 (MMP-2), MMP-9, and vascular endothelial growth factor in glioblastoma cells.
|
31106423 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, while under normoxic conditions, EGF stimulates the activation of both the PI3K and the MAPK pathways and the induction of VEGF, in glioblastoma cells, hypoxic conditions lead to the suppression of the PI3K/RhoA/C pathway and an exclusive switch to the MAPK pathway.
|
31698752 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic ablation of interleukin-1 ligands or receptor in mice bearing RCAS/tv-a-induced platelet-derived growth factor B-overexpressing glioblastoma results in reduced oedema and partial restoration of the integrity of the blood-brain barrier, respectively; similar to results obtained with vascular endothelial growth factor neutralization.
|
31665239 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, we evaluated modular peptide carrier L1 bearing CXCR4 targeting ligand for its ability to condense siRNA and facilitate endosomal escape and VEGFA gene silencing in CXCR4-expressing endothelial and glioblastoma cells.
|
31098995 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, stellettin B blocks the expression and secretion of a major proangiogenic factor, vascular endothelial growth factor (VEGF), in glioblastoma cells.
|
30769863 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Proangiogenic cytokines such as VEGF and angiopoietin-2 (Ang-2) have high expression in glioblastoma in a cell-specific manner and not only drive tumor angiogenesis and vascular permeability but also negatively regulate T-lymphocyte and innate immune cell responses.
|
31597643 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma (GB) is a hypervascular tumor with high VEGF expression which leads to development of an immuno suppressive TME.
|
31713115 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using three glioblastoma cell-lines (U87, U251, and SNB19), the adaptation of glioblastoma cells in a 1% (hypoxia) and 20% (normoxia) oxygen microenvironment on proliferation, metabolism, migration, neurosphere formation, CD133 and VEGF expression was investigated.
|
31035344 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment.
|
31040671 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, a VEGF-targeting monoclonal antibody, may trigger an infiltrative growth pattern in glioblastoma.
|
30414187 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a second line treatment of glioblastomas, the vascular endothelial growth factor (VEGF) antibody bevacizumab is administered in combination with the TOP1 inhibitor irinotecan and glioblastoma cell levels of TIMP-1 could therefore potentially influence the efficacy of such treatment.
|
28963609 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach.
|
31554364 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VM has been considered as one of the reasons that glioblastoma becomes resistant to anti-VEGF therapy.
|
30368528 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High gene expression levels of VEGFA and CXCL8 in the peritumoral brain zone are associated with the recurrence of glioblastoma: A bioinformatics analysis.
|
31788092 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.
|
30718358 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, however, BIG1 and BIG2 knockdown significantly decreased the levels of VEGF mRNA and protein in glioblastoma U251 cells and HUVECs.
|
31199673 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiogenesis mediated by vascular endothelial growth factor (VEGF) is a hallmark of glioblastoma.
|
29507055 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis.
|
30327956 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the recombinant protein Flag-L-VEGF144 and commercial VEGF protein have similar growth stimulatory activities in terms of inducing glioblastoma cell proliferation in vitro.
|
29909500 |
2018 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The VEGF polymorphism rs833061 was strongly associated with increased risk for glioma (odds ratio = 164.85) and glioblastoma (odds ratio = 155.66), confirmed after Bonferroni correction.
|
29584591 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab (BEV), a humanized monoclonal antibody that blocks the effects of vascular endothelial growth factor A, has produced impressive response rates for recurrent GB and has been approved as second-line therapy.
|
29950856 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF)-A and VEGF receptor expression in the peritumoral brain zone (PBZ) differs from that in the tumor core (TC) of glioblastoma.
|
30165233 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF mediated GDNF-induced angiogenesis in human glioblastoma.
|
30176167 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we reported a novel dual-targeting therapy for glioblastoma through simultaneous blockade of VEGF and CD47 signaling.
|
29754163 |
2018 |